Nasdaq

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology ...
Insider Monkey

Sarepta Viral Vector Gets FDA Platform Technology Designation

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FDA has granted Platform Technology ...
MarketWatch

Viral Vector Vaccines Strategic Business Research Report 2024-2030 | Expanding Pipeline of Infectious Disease Targets Strengthens the Commercial Outlook - ResearchAndMarkets.com

The "Viral Vector Vaccines - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Viral Vector Vaccines was estimated at US$773.4 Million in ...
Insider Monkey

The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy candidate SRP-9003 for limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4), ...
Business Wire

Genvira and Labskin Receive £1.2 Million ($2.0 Million) UK–Canada Collaboration Award to Advance Immunotherapies for Malignant Melanoma

OTTAWA, Ontario & YORK, England--(BUSINESS WIRE)--Genvira Biosciences Inc. (“Genvira”), a Canadian innovator in next-generation viral vectors, Labskin Limited (“Labskin”), a leader in 3D in vitro ...
Seeking Alpha

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the ...
Reuters

U.S. FDA to scrutinize vaccine design behind COVID-19 shots linked to blood clots

CHICAGO/LONDON (Reuters) - With two COVID-19 vaccines now under scrutiny for possible links to very rare cases of blood clots in the brain, U.S. government scientists are focusing on whether the ...
Business Wire

Beam Therapeutics Licenses SIRION Biotech’s LentiBOOST™ Technology for its CAR-T pipeline

MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. CAR-T cell ...
Nasdaq

FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector

Sarepta Therapeutics SRPT announced that the FDA has granted platform-technology designation to its viral vector rAAVrh74, used in the investigational gene therapy SRP-9003. This therapy is being ...
MarketWatch

Adeno-Associated Viral (AAV) Vector Market Research, Industry Trends and Global Forecasts, 2035 by Type of Therapy, Therapeutic Area, Route of Administration, Scale of ...

The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...

Viral Vector Collaboration and Licensing Agreements Analysis Report 2025: Comprehensive Listing of 413 Viral Vector Deals Announced Since 2016

The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing of 413 viral vector deals announced ...